0001140361-13-045530.txt : 20131210 0001140361-13-045530.hdr.sgml : 20131210 20131210190345 ACCESSION NUMBER: 0001140361-13-045530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131209 FILED AS OF DATE: 20131210 DATE AS OF CHANGE: 20131210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Raptor Pharmaceutical Corp CENTRAL INDEX KEY: 0001070698 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860883978 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: 9 COMMERCIAL BLVD STREET 2: SUITE 200 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-382-1390 MAIL ADDRESS: STREET 1: 9 COMMERCIAL BLVD STREET 2: SUITE 200 CITY: NOVATO STATE: CA ZIP: 94949 FORMER COMPANY: FORMER CONFORMED NAME: Raptor Pharmaceutical Corp. DATE OF NAME CHANGE: 20090929 FORMER COMPANY: FORMER CONFORMED NAME: TorreyPines Therapeutics, Inc. DATE OF NAME CHANGE: 20061003 FORMER COMPANY: FORMER CONFORMED NAME: AXONYX INC DATE OF NAME CHANGE: 19990303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAMANT VIJAY B CENTRAL INDEX KEY: 0001198238 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25571 FILM NUMBER: 131269451 MAIL ADDRESS: STREET 1: 9373 TOWNE CENTRE DRIVE SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121-3088 4 1 doc1.xml FORM 4 X0306 4 2013-12-09 0 0001070698 Raptor Pharmaceutical Corp RPTP 0001198238 SAMANT VIJAY B C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO CA 94949 1 0 0 0 Common Stock 2013-12-09 4 M 0 5000 5.13 A 5000 D Common Stock 2013-12-09 4 S 0 5000 13.8621 D 0 D Stock options (right to buy) 5.13 2013-12-09 4 M 0 5000 0 D 2011-12-22 2021-09-21 Common Stock 5000 5000 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 9, 2013. Fully vested and exercisable. This transaction was executed in multiple trades at prices ranging from $13.70 to $14.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact 2013-12-10